• +1-646-491-9876
    • +91-20-67278686

    Search

    Opioid-Induced Bowel Dysfunction Pipeline Review H1 2017

    Opioid-Induced Bowel Dysfunction Pipeline Review H1 2017

    • Report Code ID: RW0001866805
    • Category Pharmaceuticals
    • No. of Pages 26
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline landscape.

    Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-esophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

    Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) .
    - The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
    ChironWells GmbH
    RaQualia Pharma Inc
    Vitality Biopharma Inc
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Drug Profiles
    ORP-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ORP-106 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RQ-00433412 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VB-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VB-210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by ChironWells GmbH, H1 2017
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by RaQualia Pharma Inc, H1 2017
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Vitality Biopharma Inc, H1 2017
    Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    ChironWells GmbH
    RaQualia Pharma Inc
    Vitality Biopharma Inc

    Request for Sample

    Report Url https://www.reportsweb.com//opioid-induced-bowel-dysfunction-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//opioid-induced-bowel-dysfunction-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//opioid-induced-bowel-dysfunction-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments